About Our Research Program

Our Research Program focuses on the onset, neurobiology, genetics, and treatment of OCD and related conditions. Our overarching goal is to discover the causes of these disorders and, in doing so, provide the basis to develop more effective and innovative therapies to help families in the future. We have ongoing treatment studies as well as neuroimaging and genetic studies.

We are happy to discuss any of our current research studies, which include the following:

GCO#14-1390: A Prospective, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (DTMS) for the treatment of Obsessive Compulsive Disorder

Principal Investigator: Wayne Goodman, MD

The Mount Sinai Department of Psychiatry is currently recruiting for a multi-center clinical trial of HAC-coil Deep Transcranial Magnetic Stimulation (DTMS) as a treatment for Obsessive-Compulsive Disorder (OCD).
You may be eligible to participate in this study if you:

Are 22-68 years old
Have been diagnosed with OCD
Have been on SSRI medication for at least 2 months and/or are receiving psychotherapy

This research study includes 33 visits, including psychiatric assessments and 29 DTMS sessions over 12 weeks. Research subjects may be reimbursed for expenses incurred through participation in this study.

Contact: David Rosenthal, Icahn School of Medicine Department of Psychiatry, at 212-659-8803 or david.rosenthal@mssm.edu for more information.

[GCO#14-1390; MSSM IRB Approved 9/22/16]

This study is open to enrollment.

Controlled Trial of Deep Brain Stimulation for Obsessive-Compulsive Disorder
Principal Investigator: Wayne Goodman, MD

This is a multicenter study investigating the efficacy of deep brain stimulation (DBS) in treating severe treatment-resistant OCD. It is the first definitive controlled trial of a neurosurgical procedure for a severe psychiatric illness. DBS has had well-documented success in treating movement disorders such as Parkinson's. It has also demonstrated encouraging data in treating OCD. This study will use a parallel controlled design to compare effects of three months of double masked sham treatment versus active treatment DBS on reduction of OCD symptom severity.

Thirty patients will be recruited across nine study sites. The primary efficacy measure will be the Yale Brown Obsessive Compulsive Scale (YBOCS). The primary aim of the study is to determine if the effects of three months of treatment can lead to a significant improvement in YBCOS OCD severity as opposed to sham treatment. All patients will have the DBS implanted. Fifteen of the total thirty will be entered into a sham condition, that is, for the first three months they will have the system implanted but not turned on. The other fifteen will receive active treatment immediately after implantation. Patients will be followed up one week, two weeks, one month, two months, three months, and then every three months until month eighteen after implantation. Afterwards, they will be followed up for study assessments every six months. Patients must be between 18 and 75 years of age, have documented history of highly treatment resistant, severe OCD, be in good general health, be on a stable drug regimen for at least six weeks before implantation, and be able to understand and comply with instructions given by the investigators.

This study is open to enrollment.

GCO# 14-1794: The effects of Ondansetron on Brain Function

Do you have a first-degree relative with obsessive-compulsive disorder? If your parent, sibling, or child has OCD, but you yourself do not have it, you may be eligible to participate in a study of the effects of ondansetron on brain function. To learn more about participating in this study, please contact Stephanie Grimaldi at 212-824-8995 or stephanie.grimaldi@mssm.edu.

[GCO# 14-1794 – IRB Approved Through: 06/01/2016]

This study is open to enrollment.